IXICO PLC (LON:IXI, OTCMKTS:PHYOF) won a contract with its largest pharma client to provide its neuroimaging services for a new clinical trial for acute ischemic stroke.
Ischemic stroke is caused by a blockage cutting off the blood supply to the brain and is the most common form of stroke.
The new Phase II acute ischemic stroke trial will be conducted across 50 sites in North America and Europe and is worth in excess of US$0.5mln over 35 months.
While also building momentum in its growth strategy of further diversification into new therapeutic areas, the artificial intelligence (AI) data analytics company said the contract win reflects a broadening of its neurological footprint into a new therapeutic area with this client.
“We are delighted to be awarded this new study by our existing pharma client,” said Lammert Albers, the AIM-listed company's chief commercial officer.
“Having singularly focused on neurological disorders since our inception in 2004, IXICO has a long and established history of delivering advanced neuroimaging solutions to the biopharmaceutical sponsors. This new contract demonstrates our continually expanding footprint and deepening expertise within IXICO's proven specialist domain.”